Skip to content
Upcoming events
AEEDC Dubai 202719–21 January 2027World Health Expo (WHX) Dubai 202725–28 January 2027ChinaDental South China 20273–6 March 2027GermanyIDS 2027 — International Dental Show16–20 March 2027United StatesAAD Annual Meeting 202719–23 March 2027Dubai Derma 20276–8 April 2027Dental-Expo Moscow Spring 202726–29 April 2027France7th World Congress of Dermoscopy12–15 May 2027GermanyEADV Symposium 202720–22 May 2027United StatesASCO Annual Meeting 20274–8 June 2027ChinaSino-Dental 20279–12 June 2027White Nights 2027 — St. Petersburg International Oncology ForumUsually early JulyArmenian Medical World Congress 20278–10 July 2027Dental-Expo Moscow 2027Usually late SeptemberNetherlandsEADV Congress 202722–25 September 2027SpainEAO Congress 202723–25 September 2027CanadaCFAS Annual Meeting 202723–25 September 2027Russian Health Care Week 2027Usually December
Oncology

Childhood cancer survival reaches nearly 90% in the US, but gaps by race and cancer type remain

Close-up of a scientist examining samples under a microscope in a laboratory setting.

Key facts

  • A study in the Journal of the National Cancer Institute analysed US registry data on more than 100,000 children and teenagers (0–19 years) diagnosed with cancer between 1975 and 2022.
  • Five-year survival rose from about 60% in 1975 to nearly 90% for patients diagnosed by 2017.
  • For acute lymphoblastic leukemia (ALL), five-year survival rose from 43% to 95%, while acute myeloid leukemia (AML) is still around 72% and sarcomas around 74%.
  • Survival remained lower for Black patients, and some Hodgkin lymphoma survivors face higher late mortality.

What happened

Researchers at Ann & Robert H. Lurie Children’s Hospital of Chicago, led by Dr. Schwartz, published what they describe as the first comprehensive update of US childhood cancer survival statistics in more than a decade. They used the National Cancer Institute’s SEER 8 and SEER 17 registries and compared five-year overall survival across diagnoses and sociodemographic groups.

Why it matters

The headline is a large gain: roughly six in ten young patients were alive five years after diagnosis in 1975, and nearly nine in ten by 2017. The progress is uneven, though. ALL, the most common childhood cancer, accounts for much of the improvement, while AML and sarcomas still lag, and survival differed by race.

Five-year survival is also not the whole story. The authors report that people treated for Hodgkin lymphoma in the 1970s and early 1980s had 87% survival at five years but only 63% at 30 years, often because of the long-term effects of treatment.

Context: what survival figures do and do not show

Registry statistics describe populations, not individual prognosis, and the most recent diagnosis year in the analysis is 2017 so that five-year outcomes are complete. Newer treatments are therefore not yet reflected in these numbers.

What it means for clinicians and students

  • Clinicians: long-term follow-up matters as much as five-year survival, because late effects of chemotherapy and radiotherapy can appear decades later.
  • Patients and families: survival differs by cancer type, so general statistics should be discussed with the treating oncology team.
  • Dental teams: childhood cancer survivors may have long-term effects of treatment on teeth and jaw growth, so a documented treatment history is useful.
  • Students: this is a good example of how registry data (SEER) are used to track outcomes over time and to expose disparities.

Source: Lurie Children’s Hospital of Chicago press release on a peer-reviewed study in the Journal of the National Cancer Institute (DOI 10.1093/jnci/djag155), 11 November 2026.

Source: Lurie Children's Hospital of Chicago (press release on a JNCI study)